HOOKIPA PharmaHOOK 49 Current Ratio is 3.93 as of Jun. 2025, which is 12% below its 10-year median of 4.48. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, HOOKIPA Pharma ranks better than 50.39% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. HOOKIPA Pharma's current ratio for the quarter that ended in Jun. 2025 was 3.93.
HOOKIPA Pharma has a current ratio of 3.93. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for HOOKIPA Pharma's Current Ratio or its related term are showing as below:
HOOK'
s Current Ratio Range Over the Past 10 Years
Min: 3.16 Med: 4.48 Max: 17.34
Current: 3.93
During the past 8 years, HOOKIPA Pharma's highest Current Ratio was 17.34. The lowest was 3.16. And the median was 4.48.
HOOK's Current Ratio is ranked better than 50.39% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs HOOK: 3.93
HOOKIPA Pharma (OTCPK:HOOK) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
HOOKIPA Pharma Current Ratio Related Terms
HOOKIPA Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs LNAI, ZEOX, GDTC: Current Ratio Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Current Ratio of 3.93 as of Jun. 2025. This is 12% below median its historical median of 4.48. Over the past decade, HOOKIPA Pharma's Current Ratio has ranged from 3.16 to 17.34. According to the industry distribution chart, HOOKIPA Pharma ranks #703 out of 1417 companies in the Biotechnology industry, placing it in the top 49.6%.
Is HOOKIPA Pharma's Current Ratio too high?
HOOKIPA Pharma's current Current Ratio of 3.93 is 12% below median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 3.16 to a high of 17.34. The Biotechnology industry median Current Ratio is 3.89. HOOKIPA Pharma's value of 3.93 is 1% above this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #703 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Current Ratio compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #703 out of 1417 companies for Current Ratio. This puts HOOKIPA Pharma in the upper half of its industry. The industry median Current Ratio is 3.89. HOOKIPA Pharma's value of 3.93 is 1% above this benchmark. Historically, HOOKIPA Pharma's own Current Ratio has ranged from 3.16 to 17.34 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 3.89, HOOKIPA Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current Current Ratio of 3.93 is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Current Ratio is 3.93, which is 12% below median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Current Ratio is 3.93, which is 12% below median its 10-year median of 4.48 and 1% above the Biotechnology industry median of 3.89. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Current Ratio is 3.93 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
Current Ratio: 3.93 (12% below median its 10-year median of 4.48)
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
Industry Position: 1% above the Biotechnology median (#703 of 1417)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
